Ibio, INC 10-Q quarterly reports

iBio, Inc. reports significant R&D investment and progress in its preclinical pipeline, particularly for obesity and cardiometabolic diseases, while managing cash reserves and exploring strategic partnerships.

iBio, Inc. reported an increased net loss for Q1 FY2026 but significantly bolstered its cash position with $46.5 million net proceeds from an August 2025 public offering, fueling its AI-driven cardiometabolic and obesity antibody pipeline.

iBio, Inc. reports a net loss of $5.7 million for Q1 FY2026, driven by increased R&D, but strengthens its liquidity with a $46.5 million net capital raise to advance its AI-driven obesity and cardiometabolic pipeline.

iBio Inc. offers warrant holders an inducement to exercise existing warrants at a reduced price, while also reporting its financial results for the third quarter of fiscal year 2025, highlighting its focus on AI-driven antibody discovery.

iBio's Q2 2025 results highlight the company's strategic shift towards AI-driven antibody discovery, while acknowledging substantial doubt about its ability to continue as a going concern.

iBio's Q1 2025 report highlights a shift towards AI-driven antibody development, with reduced operating expenses and a focus on strategic collaborations.

iBio Inc. released its Q3 2024 results, highlighting a strategic focus on AI-driven antibody discovery while facing financial challenges and a going concern warning.

iBio Inc. released its Q2 Fiscal 2024 results, highlighting a strategic focus on AI-driven antibody discovery while navigating financial challenges and a potential going concern issue.